220 related articles for article (PubMed ID: 32557659)
1. SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy.
Benard E; Casey NP; Inderberg EM; Wälchli S
Scand J Immunol; 2020 Oct; 92(4):e12917. PubMed ID: 32557659
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer.
Leong L; Tan HL; Cua S; Yong KSM; Chen Q; Choo A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936170
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.
Terlikowska KM; Dobrzycka B; Terlikowski SJ
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800608
[TBL] [Abstract][Full Text] [Related]
4. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.
Song M; Yeku OO; Rafiq S; Purdon T; Dong X; Zhu L; Zhang T; Wang H; Yu Z; Mai J; Shen H; Nixon B; Li M; Brentjens RJ; Ma X
Nat Commun; 2020 Dec; 11(1):6298. PubMed ID: 33293516
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
6. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
[TBL] [Abstract][Full Text] [Related]
7. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
9. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
10. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
11. Prospects and challenges of CAR-T in the treatment of ovarian cancer.
Chen B; Liu J
Int Immunopharmacol; 2024 May; 133():112112. PubMed ID: 38640714
[TBL] [Abstract][Full Text] [Related]
12. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
Front Immunol; 2021; 12():638639. PubMed ID: 34177890
[TBL] [Abstract][Full Text] [Related]
13. Teaching an old dog new tricks: next-generation CAR T cells.
Tokarew N; Ogonek J; Endres S; von Bergwelt-Baildon M; Kobold S
Br J Cancer; 2019 Jan; 120(1):26-37. PubMed ID: 30413825
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Rubio MT; Galaine J; Borg C; Daguindau É
Bull Cancer; 2018 Dec; 105 Suppl 2():S135-S146. PubMed ID: 30686352
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
17. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
18. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptors for the Tumour Microenvironment.
Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
[TBL] [Abstract][Full Text] [Related]
20. Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
Shen Y; Liu G; Zhang Q; Tian X; Ouyang L; Zhang L
Immunol Lett; 2023 Mar; 255():1-9. PubMed ID: 36739093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
